Home > Healthcare > Medical Devices > Diagnostic Devices > Dermal Toxicity Testing Market

Dermal Toxicity Testing Market Trends

Report ID: GMI7561
Published Date: Dec 2023
Report Format: PDF

Download Free Sample

Dermal Toxicity Testing Market Trends

High Throughput Screening (HTS) technologies are increasingly being integrated into dermal toxicity testing. These advanced screening methods enable the rapid assessment of several substances, enhancing the efficiency of identifying potential dermal hazards.

The use of automated systems and robotics in the testing process contributes to streamlining procedures and significantly increasing throughput. This integration improves the speed and cost-effectiveness of dermal toxicity testing, making it a valuable approach in safety assessment protocols.
The high-throughput nature of these technologies accelerates the testing process compared to traditional methods. Automated systems and robotics can handle multiple samples concurrently, reducing the time required for dermal toxicity assessment. This is crucial for industries that require quick and reliable safety evaluations during product development.
Robotic systems are commonly used in HTS for dermal toxicity testing. These systems are equipped with advanced liquid handling capabilities, allowing for accurate and reproducible dispensing of test substances. The use of robotics ensures uniformity in testing conditions and reduces the potential for human errors.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

The dermal toxicity testing industry was valued at USD 2.1 billion in 2022 and is estimated to reach USD 4.5 billion by 2032 as there is a growing recognition of the ethical concerns associated with the use of animals in testing procedures.

The in-vitro testing segment had a market share of over 42% in 2022 and will grow through 2032 due to advancements in cell culture technologies that have improved the reliability and relevance of in-vitro models.

U.S. dermal toxicity testing market accounted for over USD 1.9 billion in 2022 and is predicted to witness substantial growth through 2032 owing to an increased emphasis on alternatives to traditional animal testing methods.

QIMA LTD, Charles River Laboratories, Evotec, MatTek Corporation, Eurofins Scientific, SGS Group, Intertek Group, InVivo Biosystems, Eurofins Scientific, and Qiagen N.V.